Karl Landsteiner Society

Comparison of morphological and functional parameters after switching therapy from brolucizumab to faricimab in neovascular age-related macular degeneration

Abstract Background Brolucizumab, an anti-vascular endothelial growth factor (VEGF) agent, offers extended dosing intervals in neovascular age-related macular degeneration (nAMD) but carries a rare risk of retinal vasculitis. Faricimab, a bispecific antibody targeting VEGF and an...